A comprehensive review of T-cell lymphoma following CAR T-cell immunotherapy
- 15 October 2026
- journal article
- review article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 6981-6990
Abstract
Although chimeric antigen receptor (CAR) T-cell therapy provides a potential cure for patients with non-Hodgkin B-cell lymphomas/leukemias and plasma cell myelomas, rare reports of the development of T-cell lymphomas (TCLs) in these patients have raised serious safety concerns regarding whether CAR T-cell therapy could directly contribute to the development of TCLs in a specific patient or in patients with certain types of underlying hematologic malignancies. This review aims to comprehensively evaluate the clinicodemographic features, types of TCLs, immunophenotypic characteristics, mutational profiles, and CAR T-cell transgene expression status within the lymphoma cells, as well as explore the underlying mechanisms of lymphomagenesis. A special focus is placed on the interplay between preexisting clonal hematopoiesis, immune dysregulation, and reported genomic alterations that may predispose to and/or drive T-cell lymphomagenesis. Among the total 18 reported cases, TCLs developed in patients with all types of underlying hematologic malignancies and occurred after treatment with all types of widely used commercial CAR T-cell products. Most TCLs showed aberrant T-cell phenotypes according to CD4 and/or CD8 expression. The infused CAR T-cell transgene in lymphoma cells was detected in 63% (10/16) of cases, and 73% (8/11) of cases showed the integration of the CAR transgene into a known tumor suppressor gene or oncogene. At the molecular genomic level, mutations involved in epigenetic regulators (TET2 and DNMT3A) and JAK-STAT signaling pathway, especially JAK3 mutation, were often detected. The potential mechanisms of T-cell lymphomagenesis were complex and multifactorial, including but not limited to preexisting clonal hematopoiesis of indeterminate potential, malignant transformation of CAR T cells, and lymphodepletion chemotherapy.Keywords
This publication has 58 references indexed in Scilit:
- Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapyInternational Journal of Hematology, 2025
- Treatment of an Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical ImprovementseJHaem, 2025
- Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin LymphomaJAMA Network Open, 2025
- Second Primary Cancer After Chimeric Antigen Receptor–T-Cell TherapyJAMA Oncology, 2025
- Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBaseeClinicalMedicine, 2024
- Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell TherapyJAMA Oncology, 2024
- Indolent T-Cell/Natural Killer-Cell Lymphomas/Lymphoproliferative Disorders of the Gastrointestinal Tract—What Have We Learned in the Last Decade?Laboratory Investigation, 2024
- The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19Cytotherapy, 2020
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2019
- CAR T cell therapy for B-cell lymphomasBest Practice & Research Clinical Haematology, 2018